WASHINGTON, D.C. — Pfizer Inc. and its partner BioNTech SE said on Tuesday that they had submitted an application to the U.S. health regulator for the authorization of a booster dose of their COVID-19 vaccine for children aged 5 to 11 years.

The companies earlier this month reported data from a mid-to-late stage study showing a third dose of their shot increased protection against the original coronavirus version and the Omicron variant among children in the age group.



Better than a comments section

Discuss the news on NABUR,
a place to have local conversations


The Neighborhood Alliance for Better Understanding and Respect
A site just for our local community
Focused on facts, not misinformation
Free for everyone

Join the community
What's NABUR?